Early Changes in Clinical and Laboratory Parameters in Patients Died of COVID-19

261,435,768 COVID-19 infections were detected worldwide, of them 5,207,634 deaths were registered. Identifying markers of the patient severity early in the course of the disease can facilitate the assessment of the risk of adverse outcome.

The objective: To compare values of laboratory parameters and their changes during treatment of patients with a complicated course of COVID-19 infection.

Subjects and Methods. 56 patients were included in the study, all of them were hospitalized to COVID Hospital of the Clinic of Bashkir State Medical University, Russian Ministry of Health, from September 30, 2021 to November 15, 2021, and their complicated course of the disease necessitated transfer to the intensive care unit (ICU). The laboratory evaluation included the following: a general blood and urine counts, blood chemistry including urea and creatinine, liver transaminases, and blood coagulogram (prothrombin time (PTT), prothrombin index (PTI), thrombin time, fibrinogen, and blood clotting time).

Results. In the group of patients with a fatal outcome on the day of transfer to ICU, lymphocytopenia, eosinopenia, elevated values of creatinine, total bilirubin, transaminases, C-reactive protein, D-dimer, and ferritin were noted. Also on this day, microscopic hematuria, proteinuria and cylindruria were detected in the urine tests of most patients in this group during treatment.

Conclusion. Critical deviations in the results of hematological and biochemical tests were revealed. Particular attention should be paid to such parameters as the level of erythrocytes, lymphocytes, eosinophils, glucose, urea, creatinine, total bilirubin, aspartate aminotransferase, alanine aminotransferase, creatine kinase, C-reactive protein, D-dimer, and ferritin.

1. Aleksandrovich Yu.S., Prometnoy D.V., Mironov P.I. et al. Predictors of death in severe new coronavirus infection in children. Messenger of Anesthesiology and Resuscitation, 2021, vol. 18, no. 4, pp. 29-36. (In Russ.) doi 10.21292/2078-5658-2021-18-4-29-36.

2. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19. [Provisional guidelines on prevention, diagnostics and treatment of the new coronavirus infection COVID-19)]. Rev. no. 12 as of 21.09.2021. Available:https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/%D0%92%D0%9C%D0%A0_COVID-19_V12.pdf (Accessed 01.12.2021).

3. Davtyan P.A., Gumerov R.M., Zagidullin Sh.Z. et al. Is anticoagulant therapy necessary after hospitalization with COVID-19 pneumonia? Rossiysky Kardiologicheskiy Journal, 2021, no. 26, no. S4, pp. 53-58. (In Russ.) doi 10.15829/1560-4071-2021-4652.

4. Kuzovlev A.N., Ermokhina L.V., Melnikova N.S. et al. A nomogram for predicting hospital mortality in patients with COVID-19 admitted to the intensive care unit. Messenger of Anesthesiology and Resuscitation, 2022, vol. 19, no. 1, pp. 6-17. (In Russ.) doi: 10.21292/2078-5658-2022-19-1-6-17.

5. Lavrentieva A., Tsotsolis S. Thromboembolic complications in COVID-19 disease, a brief update. Messenger of Anesthesiology and Resuscitation, 2021, vol. 18, no. 1, pp. 37-46. (In Russ.) doi: 10.21292/2078-5658-2021-18-1-37-46.

6. Lobzin Yu.V., Vilnits A.A., Kostik M.M. et al. Pediatric multisystem inflammatory syndrome associated with a new coronavirus infection: unresolved issues. Journal Infektologii, 2021, vol. 13, no. 1, pp. 13-20. (In Russ.) doi 10.22625/2072-6732-2021-13-1-13-20.

7. Malinina D.A., Shlyk I.V., Polushin Yu.S. et al. The informative value of proadrenomedullin in patients with severe COVID-19. Messenger of Anesthesiology and Resuscitation, 2020, vol. 17, no. 6, pp. 31-38. (In Russ.) doi: 10.21292/2078-5658-2020-17-6-31-38.

8. Polushin Yu.S., Shlyk I.V., Gavrilova E.G. et al. Catastrophic antiphospholipid COVID-19 syndrome. Messenger of Anesthesiology and Resuscitation, 2021, vol. 18, no. 1, pp. 17-26. (In Russ.) doi: 10.21292/2078-5658-2021-18-1-17-26.

9. Polushin Yu.S., Shlyk I.V., Gavrilova E.G. et al. The role of ferritin in assessing COVID-19 severity. Messenger of Anesthesiology and Resuscitation, 2021, vol. 18, no. 4, pp. 20-28. (In Russ.) doi: 10.21292/2078-5658-2021-18-4-20-28.

10. Pshenisnov K.V., Aleksandrovich Yu.S., Lipin A.S. et al. Predictors of the outcome of severe polytrauma in children: a retrospective cohort multicenter study. Vestnik Intensivnoy Terapii Im. А.I. Saltanova, 2021, no. 4, pp. 69-78. (In Russ.) doi 10.21320/1818-474X-2021-4-69-78.

11. Samorodov A.V., Zolotukhin K.N., Zabolotsky D.V. et al. Specific parameters of the thromboelastographic profile of patients with COVID-19 in the intensive care unit. Messenger of Anesthesiology and Resuscitation, 2020, vol. 17, no. 6, pp. 39-44. (In Russ.) doi: 10.21292/2078-5658-2020-17-6-39-44.

12. Cai Q., Huang D., Yuet H. et al. COVID-19: Abnormal liver function tests. J. Hepatol., 2020, vol. 73, no. 3, pp. 566-574. doi:10.1016/j.jhep.2020.04.006.

13. Chalmers S., Khawaja A., Wieruszewski P.M. et al. Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: the role of inflammatory biomarkers. World J. Crit. Care Med., 2019, vol. 8, no. 5, pp. 59. doi:10.5492/wjccm.v8.i5.59.

14. Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, vol. 395, no. 10223, pp. 507-513. doi:10.1016/S0140-6736(20)30211-7.

15. Cheng Y., Luo R., Wang K. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Intern., 2020, vol. 97, no. 5, pp. 829-838. doi:10.1016/j.kint.2020.03.005.

16. Deng Y., Liu W., Liu K. et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chinese Med. J., 2020, vol. 133, no. 11, pp. 1261-1267. doi:10.1097/CM9.0000000000000824.

17. Escalera-Antezana J.P., Lizon-Ferrufino N.F., Maldonado-Alanoca A. et al. Clinical features of the first cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain. Travel Med. Infect. Dis., 2020, vol. 35, pp. 101653. doi:10.1016/j.tmaid.2020.101653.

18. Fan Z., Chen L., Li J. et al. Clinical features of COVID-19-related liver functional abnormality. Clin. Gastroent. Hepat., 2020, vol. 18, no. 7, pp. 1561‒1566. doi:10.1016/j.cgh.2020.04.002.

19. Garcia-Olivé I., Sintes H., Radua J. et al. D-dimer in patients infected with COVID-19 and suspected pulmonary embolism. Respir. Med., 2020, vol. 169, pp. 106023. doi:10.1016/j.rmed.2020.106023.

20. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, no. 10223, pp. 497-506. doi:10.1016/S0140-6736(20)30183-5.

21. Huang I., Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J. Intens. Care, 2020, vol. 8, no. 1, pp. 1-10. doi:10.1186/s40560-020-00453-4.

22. Iba T., Levy J.H. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J. Thromb. Haemostasis, 2018, vol. 16, no. 2, pp. 231-241. doi:10.1111/jth.13911.

23. Liao Y.C. et al. IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α. J. Immunol., 2002, vol. 169, no. 8, pp. 4288-4297. doi:10.4049/jimmunol.169.8.4288.

24. Liu F., Li L., Meng D.X. et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J. Clin. Virology, 2020, vol. 127, pp. 104370. doi:10.1016/j.jcv.2020.104370.

25. Meijs D.A.M., van Bussel B.C.T., Stessel B. et al. Better COVID-19 Intensive Care Unit survival in females, independent of age, disease severity, comorbidities, and treatment. Sci. Reports, 2022, vol. 12, no. 1, pp. 1-9. doi. org/10.1038/s41598-021-04531-x.

26. Panteleev V., Nartaylakov M., Mustafin A. et al. Surgical treatment of liver echinococcosis and alveococcosis. Infez. Med., 2019, vol. 27, no. 4, pp. 422-428.

27. Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol., 2020, vol. 38, no. 1, pp. 1-9. doi: 10.12932/AP-200220-0772.

28. Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis., 2020, vol. 71, no. 15, pp. 762-768. doi:10.1093/cid/ciaa248.

29. Urakov A.L., Bashirova L.I., Mustafin I.G. et al. Thromboelastography as an instrument of preclinical studies of the potential drug. J. Appl. Pharm. Sci., 2020, vol. 10, no. 8, pp. 105-110. doi 10.7324/JAPS.2020.10812.

30. Wang F., Hou H., Luo Y. et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight, 2020, vol. 5, no. 10, pp. e137799. doi:10.1172/jci.insight.137799.

31. Wang L. C-reactive protein levels in the early stage of COVID-19. Medecine Et Maladies Infectieuses, 2020, vol. 50, no. 4, pp. 332-334. doi:10.1016/j.medmal.2020.03.007.

32. Xu H., Zhong L., Deng J. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci., 2020, vol. 12, no. 1, pp. 1-5. doi:10.1038/s41368-020-0074-x.

33. Yang L., Luo W., Zhang Q. et al. Cardamonin inhibits LPS-induced inflammatory responses and prevents acute lung injury by targeting myeloid differentiation factor 2. Phytomedicine, 2021, no. 153785. doi: 10.1016/j.phymed.2021.153785.

34. Ye L., Chen X., Wang M. et al. Curcumin analogue C66 attenuates obesity-induced myocardial injury by inhibiting JNK-mediated inflammation. Biomed Pharmacother., 2021, vol. 143, pp. 112-121. doi: 10.1016/j.biopha.2021.112121.

35. Yu B., Li X., Chen J. et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J. Thromb. Thrombolysis, 2020, vol. 50, no. 3, pp. 548-557. doi:10.1007/s11239-020-02171-y.

36. Zhang L., Yan X., Fanet Q. et al. D-dimer levels on admission to predict inhospital mortality in patients with COVID-19. J. Thromb. Haemostasis, 2020, vol. 18, no. 6, pp. 1324-1329. doi:10.1111/jth.14859.

37. Zhao Q., Meng M., Kumar R. et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int. J. Infect. Dis., 2020, vol. 96, pp. 131-135. doi:10.1016/j.ijid.2020.04.086.